Trial Profile

An accelerated pivotal phase 2 registrational trial of MB-106 in Waldenstrom macroglobulinemia (WM)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB-106 (Primary)
Indications Waldenstrom's macroglobulinaemia
Focus Registrational; Therapeutic Use

Most Recent Events

11 Mar 2024 According to a Mustang Bio media release, the company expects to treat the first patient in the second half of 2024, which could enable topline results in the second half of 2026.
21 Nov 2023 New trial record
14 Nov 2023 According to a Mustang Bio media release, the company expects to start this study in mid-2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com